Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Non-inferiority of Cysticlean versus fosfomycin for acute cystitis in women
2018-001448-78Phase 4Terminated
- Sponsor
- Vita Green Europa S.A.
- Start
- Oct 2018
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Cysticlean in acute cystitis and urinary tract infection (UTI) (2 arms), sponsored by Vita Green Europa S.A. Primary endpoint: Treatment failure-free rate. Started Oct 2018; status: terminated.
02
Drugs
Cysticlean
03
Conditions
acute cystitisurinary tract infection (UTI)
Beyond the preview
Go deeper on 2018-001448-78.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001448-78.